Cargando…

Positron emission tomography/computed tomography dual imaging using 18-fluorine flurodeoxyglucose and (11)C-labeled 2-β-carbomethoxy-3-β-(4-fluorophenyl) tropane for the severity assessment of Parkinson disease

The value of dual imaging mode for the severity assessment of Parkinson disease (PD) is explored by conducting positron emission tomography computed tomography (PET/CT) double imaging using combined 18-fluorine flurodeoxyglucose ((18)F-FDG) brain metabolism and 11C-2β-carbomethoxy-3β-(4-fluorophenyl...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Xiaohong, Zhang, Qizhou, Qin, Yongde, Li, Yubin, Mutaerbieke, Nazimuguli, Zhao, Xiaojia, Yibulayin, Amina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7440190/
https://www.ncbi.nlm.nih.gov/pubmed/32243399
http://dx.doi.org/10.1097/MD.0000000000019662
_version_ 1783573120014090240
author Li, Xiaohong
Zhang, Qizhou
Qin, Yongde
Li, Yubin
Mutaerbieke, Nazimuguli
Zhao, Xiaojia
Yibulayin, Amina
author_facet Li, Xiaohong
Zhang, Qizhou
Qin, Yongde
Li, Yubin
Mutaerbieke, Nazimuguli
Zhao, Xiaojia
Yibulayin, Amina
author_sort Li, Xiaohong
collection PubMed
description The value of dual imaging mode for the severity assessment of Parkinson disease (PD) is explored by conducting positron emission tomography computed tomography (PET/CT) double imaging using combined 18-fluorine flurodeoxyglucose ((18)F-FDG) brain metabolism and 11C-2β-carbomethoxy-3β-(4-fluorophenyl) tropane ((11)C-CFT) brain dopamine transporter (DAT). A total of 102 patients with PD and 50 healthy people in the control group are enrolled for the PET/CT dual imaging of (18)F-FDG brain metabolism and (11)C-CFT brain DAT. The characteristics of (18)F-FDG PET/CT and (11)C-CFT PET/CT imaging are analyzed by delineating the region of interest. Differences in the glucose metabolism and DAT distribution in the basal ganglia of patients with PD and healthy control group in the PET/CT imaging and the radioactive distribution characteristics of cerebral cortex in glucose metabolism imaging are compared. The characteristics of PET/CT imaging of (11)C-CFT brain DAT in the ganglion region in absorbing (11)C-CFT in different PD groups are analyzed. Compared with the healthy control group, changes in the cerebral glucose metabolism in the PD group mainly occur due to the increased symmetry metabolism of the nucleus of bilateral basal ganglia and the decreased metabolism of the cerebral cortex as shown in the (18)F-FDG PET/CT images. With disease progression, the bilateral parietal, frontal, temporal, and occipital leaves showed different degrees of FDG metabolism. Statistically significant difference is observed for the(11)C-CFT absorption among the caudate nucleus and the anterior, middle, and posterior nuclei of the bilateral basal ganglia of the PD and healthy control groups. In the PD group, the bilateral caudate nucleus and the anterior, middle, and posterior parts of the putamen show decreased DAT distribution. Regardless of unilateral or bilateral symptoms, the DAT distribution in the nucleus of the contralateral basal ganglia and in the posterior part of the nucleus is substantially reduced. PET/CT dual imaging by (18)F-FDG PET/CT combined with (11)C-CFT PET/CT features high application value for the severity assessment of PD.
format Online
Article
Text
id pubmed-7440190
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-74401902020-09-04 Positron emission tomography/computed tomography dual imaging using 18-fluorine flurodeoxyglucose and (11)C-labeled 2-β-carbomethoxy-3-β-(4-fluorophenyl) tropane for the severity assessment of Parkinson disease Li, Xiaohong Zhang, Qizhou Qin, Yongde Li, Yubin Mutaerbieke, Nazimuguli Zhao, Xiaojia Yibulayin, Amina Medicine (Baltimore) 6800 The value of dual imaging mode for the severity assessment of Parkinson disease (PD) is explored by conducting positron emission tomography computed tomography (PET/CT) double imaging using combined 18-fluorine flurodeoxyglucose ((18)F-FDG) brain metabolism and 11C-2β-carbomethoxy-3β-(4-fluorophenyl) tropane ((11)C-CFT) brain dopamine transporter (DAT). A total of 102 patients with PD and 50 healthy people in the control group are enrolled for the PET/CT dual imaging of (18)F-FDG brain metabolism and (11)C-CFT brain DAT. The characteristics of (18)F-FDG PET/CT and (11)C-CFT PET/CT imaging are analyzed by delineating the region of interest. Differences in the glucose metabolism and DAT distribution in the basal ganglia of patients with PD and healthy control group in the PET/CT imaging and the radioactive distribution characteristics of cerebral cortex in glucose metabolism imaging are compared. The characteristics of PET/CT imaging of (11)C-CFT brain DAT in the ganglion region in absorbing (11)C-CFT in different PD groups are analyzed. Compared with the healthy control group, changes in the cerebral glucose metabolism in the PD group mainly occur due to the increased symmetry metabolism of the nucleus of bilateral basal ganglia and the decreased metabolism of the cerebral cortex as shown in the (18)F-FDG PET/CT images. With disease progression, the bilateral parietal, frontal, temporal, and occipital leaves showed different degrees of FDG metabolism. Statistically significant difference is observed for the(11)C-CFT absorption among the caudate nucleus and the anterior, middle, and posterior nuclei of the bilateral basal ganglia of the PD and healthy control groups. In the PD group, the bilateral caudate nucleus and the anterior, middle, and posterior parts of the putamen show decreased DAT distribution. Regardless of unilateral or bilateral symptoms, the DAT distribution in the nucleus of the contralateral basal ganglia and in the posterior part of the nucleus is substantially reduced. PET/CT dual imaging by (18)F-FDG PET/CT combined with (11)C-CFT PET/CT features high application value for the severity assessment of PD. Wolters Kluwer Health 2020-04-03 /pmc/articles/PMC7440190/ /pubmed/32243399 http://dx.doi.org/10.1097/MD.0000000000019662 Text en Copyright © 2020 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nc/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc/4.0
spellingShingle 6800
Li, Xiaohong
Zhang, Qizhou
Qin, Yongde
Li, Yubin
Mutaerbieke, Nazimuguli
Zhao, Xiaojia
Yibulayin, Amina
Positron emission tomography/computed tomography dual imaging using 18-fluorine flurodeoxyglucose and (11)C-labeled 2-β-carbomethoxy-3-β-(4-fluorophenyl) tropane for the severity assessment of Parkinson disease
title Positron emission tomography/computed tomography dual imaging using 18-fluorine flurodeoxyglucose and (11)C-labeled 2-β-carbomethoxy-3-β-(4-fluorophenyl) tropane for the severity assessment of Parkinson disease
title_full Positron emission tomography/computed tomography dual imaging using 18-fluorine flurodeoxyglucose and (11)C-labeled 2-β-carbomethoxy-3-β-(4-fluorophenyl) tropane for the severity assessment of Parkinson disease
title_fullStr Positron emission tomography/computed tomography dual imaging using 18-fluorine flurodeoxyglucose and (11)C-labeled 2-β-carbomethoxy-3-β-(4-fluorophenyl) tropane for the severity assessment of Parkinson disease
title_full_unstemmed Positron emission tomography/computed tomography dual imaging using 18-fluorine flurodeoxyglucose and (11)C-labeled 2-β-carbomethoxy-3-β-(4-fluorophenyl) tropane for the severity assessment of Parkinson disease
title_short Positron emission tomography/computed tomography dual imaging using 18-fluorine flurodeoxyglucose and (11)C-labeled 2-β-carbomethoxy-3-β-(4-fluorophenyl) tropane for the severity assessment of Parkinson disease
title_sort positron emission tomography/computed tomography dual imaging using 18-fluorine flurodeoxyglucose and (11)c-labeled 2-β-carbomethoxy-3-β-(4-fluorophenyl) tropane for the severity assessment of parkinson disease
topic 6800
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7440190/
https://www.ncbi.nlm.nih.gov/pubmed/32243399
http://dx.doi.org/10.1097/MD.0000000000019662
work_keys_str_mv AT lixiaohong positronemissiontomographycomputedtomographydualimagingusing18fluorineflurodeoxyglucoseand11clabeled2bcarbomethoxy3b4fluorophenyltropanefortheseverityassessmentofparkinsondisease
AT zhangqizhou positronemissiontomographycomputedtomographydualimagingusing18fluorineflurodeoxyglucoseand11clabeled2bcarbomethoxy3b4fluorophenyltropanefortheseverityassessmentofparkinsondisease
AT qinyongde positronemissiontomographycomputedtomographydualimagingusing18fluorineflurodeoxyglucoseand11clabeled2bcarbomethoxy3b4fluorophenyltropanefortheseverityassessmentofparkinsondisease
AT liyubin positronemissiontomographycomputedtomographydualimagingusing18fluorineflurodeoxyglucoseand11clabeled2bcarbomethoxy3b4fluorophenyltropanefortheseverityassessmentofparkinsondisease
AT mutaerbiekenazimuguli positronemissiontomographycomputedtomographydualimagingusing18fluorineflurodeoxyglucoseand11clabeled2bcarbomethoxy3b4fluorophenyltropanefortheseverityassessmentofparkinsondisease
AT zhaoxiaojia positronemissiontomographycomputedtomographydualimagingusing18fluorineflurodeoxyglucoseand11clabeled2bcarbomethoxy3b4fluorophenyltropanefortheseverityassessmentofparkinsondisease
AT yibulayinamina positronemissiontomographycomputedtomographydualimagingusing18fluorineflurodeoxyglucoseand11clabeled2bcarbomethoxy3b4fluorophenyltropanefortheseverityassessmentofparkinsondisease